1219000-72-2

Basic information

• Product Name: (2S,3R,4R,5S,6S)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(iodomethyl)tetrahydro-2H-pyran-3,4,5-triol
• Synonyms: (2S,3R,4R,5S,6S)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(iodomethyl)tetrahydro-2H-pyran-3,4,5-triol
• CAS NO: 1219000-72-2
• Molecular Weight: 518.776
• Mol File: 1219000-72-2.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: (2S,3R,4R,5S,6S)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(iodomethyl)tetrahydro-2H-pyran-3,4,5-triol(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,3R,4R,5S,6S)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(iodomethyl)tetrahydro-2H-pyran-3,4,5-triol(1219000-72-2)
• EPA Substance Registry System: (2S,3R,4R,5S,6S)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(iodomethyl)tetrahydro-2H-pyran-3,4,5-triol(1219000-72-2)

Safety Data

• Hazardous Substances Data: 1219000-72-2(Hazardous Substances Data)

Upstream product

• 461432-26-8 dapagliflozin 

Downstream Products

• 1219000-73-3 3-({(2R,3S,4R,5R,6S)-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-3,4,5-trihydroxy-tetrahydro-pyran-2-ylmethyl}-amino)-N-methyl-benzamide 
• 1290629-90-1 (5S,6R,7R,8S)-5-[3-(4-ethoxy-benzyl)-phenyl]-1-hydroxymethyl-4-oxa-spiro[2.5]octane-6,7,8-triol 
• 1290629-89-8 (5S,6R,7R,8S)-5-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-1-hydroxymethyl-4-oxa-spiro[2.5]octane-6,7,8-triol 
• 1290629-88-7 {(5S,6S,7R,8S)-6,7,8-tris-benzyloxy-5-[3-(4-ethoxy-benzyl)-phenyl]-4-oxa-spiro[2.5]oct-1-yl}-methanol 
• 1290629-87-6 {(5S,6S,7R,8S)-6,7,8-tris-benzyloxy-5-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-4-oxa-spiro[2.5]oct-1-yl}-methanol 
• 1290629-86-5 (5S,6S,7R,8S)-6,7,8-tris-benzyloxy-5-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-4-oxa-spiro[2.5]octane-1-carboxylic acid ethyl ester 
• 1290629-76-3 (5S,6S,7R,8S)-5-(4-chloro-3-{4-[(S)-(tetrahydro-furan-3-yl)oxy]-benzyl}phenyl)-4-oxaspiro[2.5]octane-6,7,8-triol 
• 1290629-75-2 (5S,6S,7R,8S)-5-(4-chloro-3-(4-((S)-tetrahydrofuran-3-yloxy)benzyl)phenyl)-4-oxaspiro[2.5]octane-6,7,8-triyl triacetate 
• 1290629-74-1 (5S,6R,7R,8S)-5-[4-chloro-3-(4-hydroxy-benzyl)-phenyl]-4-oxa-spiro[2.5]octane-6,7,8-triol 
• 1290629-73-0 acetic acid (5S,6S,7R,8S)-7,8-diacetoxy-5-[4-chloro-3-(4-hydroxy-benzyl)-phenyl]-4-oxa-spiro[2.5]oct-6-yl ester 
• 1290629-72-9 acetic acid (5S,6S,7R,8S)-7,8-diacetoxy-5-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-4-oxa-spiro[2.5]oct-6-yl ester 
• 1290629-70-7 (5S,6R,7R,8S)-5-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-4-oxa-spiro[2.5]octane-6,7,8-triol 
• 1290629-69-4 (5S,6S,7R,8S)-6,7,8-tris-benzyloxy-5-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-4-oxa-spiro[2.5]octane 
• 1290629-68-3 (2S,3S,4R,5S)-3,4,5-tris-benzyloxy-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-methylene-tetrahydro-pyran 

Relevant articles and documents

Copper-Catalyzed Difluoromethylation of Alkyl Iodides Enabled by Aryl Radical Activation of Carbon–Iodine Bonds

The engagement of unactivated alkyl halides in copper-catalyzed cross-coupling reactions has been historically challenging, due to their low reduction potential and the slow oxidative addition of copper(I) catalysts. In this work, we report a novel strategy that leverages the halogen abstraction ability of aryl radicals, thereby engaging a diverse range of alkyl iodides in copper-catalyzed Negishi-type cross-coupling reactions at room temperature. Specifically, aryl radicals generated via copper catalysis efficiently initiate the cleavage of the carbon–iodide bonds of alkyl iodides. The alkyl radicals thus generated enter the copper catalytic cycles to couple with a difluoromethyl zinc reagent, thus furnishing the alkyl difluoromethane products. This unprecedented Negishi-type difluoromethylation approach has been applied to the late-stage modification of densely functionalized pharmaceutical agents and natural products.

GLUCOSIDE DERIVATIVES AND USES THEREOF

The present invention relates to compounds of formula I and pharmaceutically acceptable salts thereof, and to formulations and uses of the compounds of formula (I) in the treatment of metabolic disorders.

GLUCOSIDE DERIVATIVES AND USES THEREOF AS SGLT INHIBITORS

The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts, to formulations and uses in the treatment of metabolic disorders.